CGMs for Early Diabetes: Should You?
- Continuous glucose monitors (CGMs) are gaining traction as a tool for managing early type 2 diabetes and prediabetes.
- CGMs,available by prescription and over the counter,measure glucose levels through a small sensor placed under the skin.
- Mihail Zilbermint, MD, an associate professor at Johns hopkins University School of Medicine, advocates for the strategic use of CGMs in prediabetes.
Discover if continuous glucose monitors (CGMs) are right for you if you have prediabetes or early type 2 diabetes. CGMs show promise in supporting behavioral changes and may reveal patterns linking diet,sleep,and stress too glucose levels.News Directory 3 explores how these devices,available by prescription and over the counter,provide real-time feedback,but also notes that access and long-term data pose challenges.Doctors such as Anne Peters and Mihail Zilbermint are cited; they believe that the tech can be transformational if used strategically. The article reviews the need for personalized data interpretation to sidestep distress, with a look at both the pros and cons of this emerging technology. Are CGMs the future? Discover what’s next for early diabetes management.
Continuous Glucose Monitors Show Promise in Early Diabetes Management
Continuous glucose monitors (CGMs) are gaining traction as a tool for managing early type 2 diabetes and prediabetes. Emerging evidence suggests that CGMs can provide valuable insights, supporting behavior changes and personalized risk assessment for patients. While experts see great potential in using CGMs for early diabetes management, barriers to access and a lack of long-term data remain.
CGMs,available by prescription and over the counter,measure glucose levels through a small sensor placed under the skin. This allows for trend analysis, time-in-range tracking, and identification of blood glucose fluctuations. Anne Peters, MD, director of the university of Southern California’s Clinical Diabetes Programs, notes that these features help patients connect diet, sleep, stress, and activity with glycemic variability, revealing crucial patterns.
Mihail Zilbermint, MD, an associate professor at Johns hopkins University School of Medicine, advocates for the strategic use of CGMs in prediabetes. He believes they can transform patient engagement by providing real-time feedback,making the invisible visible. Studies suggest that CGM use can improve food choices, physical activity, and overall glycemic variability, even in people without diabetes.
A study in Diabetes, Obesity and Metabolism found that CGMs, combined with education, led to weight loss and improved cholesterol levels in people with type 2 diabetes and prediabetes. Additional research indicates that CGM use with personalized nutrition therapy doubled weight loss and fat reduction in individuals with prediabetes.
Despite the potential benefits, long-term randomized controlled trials supporting routine CGM use in these populations are lacking. The American Diabetes Association and the Endocrine Society acknowledge the potential of CGMs but do not currently recommend thier routine use in those with prediabetes or type 2 diabetes who are not on insulin or other glucose-lowering agents.
Kevin Miller, DO, a family physician and member of the American Diabetes Association’s Primary Care Committee, emphasizes the need for more research. He likens CGMs to a speedometer, providing data to gauge glucose levels. However, cost and coverage barriers exist, as most insurance companies do not cover CGMs unless a patient uses insulin, and over-the-counter costs can be prohibitive.
Peters notes that the populations at highest risk for prediabetes and type 2 diabetes often come from underserved communities with limited access. She observed improved outcomes when providing CGMs to patients in her East Los Angeles clinic, as recognizing glucose spikes changed behavior irrespective of education or health literacy.
Clinics sometimes use sample CGMs intermittently to support behavior change. Even short-term use can help patients track changes. However, a lack of standardization for what is considered normal glucose levels poses a challenge for physicians.
“I am a strong advocate for the strategic use of CGMs in prediabetes… They have a great potential to transform how we engage patients who are at risk; they provide real-time feedback, making invisible things visible.”
“I think CGMs are great because they make people aware of the composition of their food… if a patient starts to notice that eating cereal for breakfast increases their blood sugar level to 200 mg/dL, they may stop eating cereal for breakfast — and be healthier for it.”
Zilbermint notes that even experienced clinicians struggle to interpret CGM data in people without diagnosed diabetes.He believes diabetes technology, including CGMs, is a notable advancement, even though some colleagues have a more cautious approach, especially in people without diabetes.
“We don’t want to measure to the point where it can backfire and add distress.”
CGMs can be powerful tools for select patients,especially those with type 2 diabetes on medications,as well as those with prediabetes or early diabetes. Guided data interpretation is essential, and CGM use should be considered within the broader context of a patient’s lifestyle and capacity.
What’s next
Greater systemic physician education around CGM use is needed. Physicians less familiar with CGMs can empower interested patients to explore over-the-counter options and check back in with data for shared decision-making. Follow-up appointments initiated by the provider are key to meaningful progress in continuous glucose monitoring for early diabetes.